Oxford BioMedica

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Oxford BioMedica sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Oxford BioMedica: 6 sponsored US clinical trials, none currently recruiting.

Oxford BioMedica sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Carcinoma, Renal Cell, with 2 trials.

Upper-quartile sponsor footprint

Oxford BioMedica sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

NCT01678872
COMPLETED Phase 1

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

NCT01301443
TERMINATED Phase 2

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
COMPLETED Phase 3

TroVax Renal Immunotherapy Survival Trial

NCT00397345
COMPLETED Phase 2

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

NCT00325507
COMPLETED Phase 2

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

NCT00083941

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 1

Therapeutic Areas

Carcinoma, Renal Cell 2
Clear Cell Renal Carcinoma 1
Age-related Macular Degeneration 1

How the Oxford BioMedica early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 4 completed (67%).

Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Carcinoma, Renal Cell (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Oxford BioMedica: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Oxford BioMedica sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Oxford BioMedica23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Oxford BioMedica sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Oxford BioMedica sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Oxford BioMedica page

6 registered trials is a research-attention snapshot, not an endorsement of Oxford BioMedica or any single study.

  • None of Oxford BioMedica's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Carcinoma, Renal Cell is the condition Oxford BioMedica studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Carcinoma, Renal Cell trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Oxford BioMedica pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.